RUBINSTEIN JULIE sold $954K of ADPT
RUBINSTEIN JULIE (President and COO) sold 35,643 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $26.78 ($25.78–$27.88, $0.95M total) across 7 trades over 2026-11-04 to 2026-11-06 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
A modest insider sell by a top executive may be interpreted as a slight negative signal, but the small amount limits market impact.
Market read
First‑report insider sale of under $1M; limited trading relevance but provides a data point for monitoring executive sentiment.
What to watch
Potential upcoming corporate actions or financing needs that prompted the sale are not disclosed.
Background
SEC Form 4 filing discloses insider transactions, providing primary‑source information on executive share sales.
Ticker impact
President and COO Julie Rubinstein sold 35,643 shares for $954,442 via a 10b5-1 plan, reducing her stake to 377,802 shares.
likely modest pressure as the market prices in the insider sell
Sale size is under $1M and the insider is a senior executive, which can be viewed as a minor negative signal but unlikely to move the stock significantly.
Market effects
none
none
none
Counterpoint
The sale could be routine under a pre‑arranged plan and not reflect any negative outlook, so the stock may remain stable.
Key entities
- companyAdaptive Biotechnologies Corp
US‑listed biotech company (ticker ADPT) whose President and COO sold shares.
- personJulie Rubinstein
President and COO of Adaptive Biotechnologies, executing a 10b5‑1 sale.



